Click to view your profile
Click to search for condition or expert
Click to open main menu
Axial Spondyloarthritis (AxSpA) Latest Advances
Find the Latest Research About Axial Spondyloarthritis (AxSpA)
Save
Bookmark
Share
Share
Overview
Find a Doctor
Latest Advances
Clinical Trials
Treatments
Customize your search results with filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/06/2023
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications
See more filters
News in the treatment of axial spondyloarthritis.
Condition:
Axial Spondyloarthritis
Journal:
Vnitrni lekarstvi
Treatment Used:
Tumor Necrosis Factor α and Interleukin-17 Inhibitors
Number of Patients:
0
Published:
October 25, 2022
VIEW PUBLICATION
Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Condition:
Axial Spondyloarthritis (SpA)
Journal:
Drug design, development and therapy
Treatment Used:
Upadacitinib
Number of Patients:
0
Published:
October 21, 2022
VIEW PUBLICATION
A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis.
Condition:
Axial Spondyloarthritis (axSpA)
Journal:
Drug design, development and therapy
Treatment Used:
Imrecoxib
Number of Patients:
163
Published:
August 29, 2022
VIEW PUBLICATION
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
Condition:
Enthesitis-Related Arthritis (ERA) and Juvenile Psoriatic Arthritis (JPsA)
Journal:
Annals of the rheumatic diseases
Treatment Used:
Secukinumab
Number of Patients:
86
Published:
August 12, 2022
VIEW PUBLICATION
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Condition:
Axial Spondyloarthritis
Journal:
Lancet (London, England)
Treatment Used:
Upadacitinib
Number of Patients:
314
Published:
July 31, 2022
VIEW PUBLICATION
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
Condition:
Axial Spondyloarthritis (AxSpA)
Journal:
RMD open
Treatment Used:
Ixekizumab (IXE)
Number of Patients:
932
Published:
July 19, 2022
VIEW PUBLICATION
Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.
Condition:
Rheumatic and Musculoskeletal Diseases (RMDs)
Journal:
RMD open
Treatment Used:
Diet
Number of Patients:
0
Published:
June 02, 2022
VIEW PUBLICATION
Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials.
Condition:
Ankylosing Spondylitis
Journal:
Seminars in arthritis and rheumatism
Treatment Used:
Biologics
Number of Patients:
3481
Published:
March 27, 2022
VIEW PUBLICATION
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Condition:
Axial Spondylarthritis (axSpA)
Journal:
Rheumatology (Oxford, England)
Treatment Used:
Conventional Synthetic Disease-Modifying Antirheumatic Drug (csDMARD) Combined with TNF Inhibitor
Number of Patients:
24171
Published:
March 24, 2022
VIEW PUBLICATION
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.
Condition:
Axial Spondyloarthritis (axSPpA)
Journal:
RMD open
Treatment Used:
Certolizumab Pegol (CZP)
Number of Patients:
317
Published:
March 17, 2022
VIEW PUBLICATION
Treatment of axial spondyloarthritis: an update.
Condition:
Axial Spondyloarthritis (axSpA)
Journal:
Nature reviews. Rheumatology
Treatment Used:
Physical Therapy, Exercise, NSAIDs, TNF Inhibitors, IL-17 Inhibitors, Biologics, and JAK Inhibitors
Number of Patients:
0
Published:
March 11, 2022
VIEW PUBLICATION
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Condition:
Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis
Journal:
Acta dermato-venereologica
Treatment Used:
Secukinumab
Number of Patients:
12637
Published:
February 11, 2022
VIEW PUBLICATION
Showing 1-12 of 66
Next
Last Updated: 01/06/2023